Canine atopic dermatitis is one of the most prevalent dermatological conditions in clinical practice, accounting for a significant proportion of veterinary consultations.
Canine Atopic Dermatitis management is a central challenge in veterinary dermatology due to the chronic, multifactorial nature of the disease.
This chronic, pruritic inflammatory skin disease substantially impairs canine quality of life and often places a long-term burden on pet owners because of frequent veterinary visits and lifelong treatment requirements.
Fortunately, recent advances in veterinary pharmacology and immunology have expanded the therapeutic arsenal, enabling more effective and targeted disease control.
Pathogenesis of Canine Atopic Dermatitis
The pathogenesis of canine atopic dermatitis is complex and not yet fully understood. It is widely accepted to be multifactorial, involving:
Genetic predisposition
Immune dysregulation
Epidermal barrier dysfunction
Allergic sensitization to environmental allergens
This interplay of factors results in chronic inflammation, heightened pruritus, and recurrent skin lesions.
Clinical Signs and Symptoms of Canine Atopic Dermatitis
Typical Presentation
The age of onset for atopic dermatitis in dogs generally ranges between 6 months and 3 years. Hallmark clinical signs include:
Persistent or recurrent pruritus
Characteristic lesion distribution affecting:
Paws
Face
Ears
Axillae
Ventral abdomen
Laboratory findings may show elevated serum IgE levels, although this is not diagnostic.
Secondary Complications
Secondary bacterial and yeast infections, particularly involving Staphylococcus spp. and Malassezia spp., are common and frequently exacerbate clinical signs.
Diagnosis of Atopic Dermatitis in Dogs
Diagnosis is primarily clinical and exclusionary, based on:
Detailed patient history
Compatible clinical signs
Elimination of other pruritic diseases, including:
Ectoparasites (fleas, scabies, demodicosis)
Microbial dermatitis
Other allergic skin diseases (food allergy, contact dermatitis)
Canine Atopic Dermatitis Management: A Multimodal Approach
Cytopoint® is a monoclonal antibody targeting IL-31, a key mediator of neurogenic pruritus.
Injectable therapy
Provides relief for several weeks
Simplifies treatment compliance for pet owners
Antihistamines
Despite widespread use, antihistamines offer limited efficacy in canine atopic dermatitis due to the disease’s complex inflammatory pathways.
Allergen-Specific Immunotherapy
Allergen-Specific Immunotherapy (oral or injectable) involves gradual exposure to relevant allergens to induce immune tolerance and remains the only disease-modifying therapy for canine atopic dermatitis.
Dietary Management
Elimination diets are essential to rule out food allergies
Functional diets formulated for canine atopic dermatitis are increasingly available
Modern canine atopic dermatitis management has evolved significantly, driven by innovations in targeted immunomodulatory therapies, biologics, and specialized nutrition. For veterinarians and veterinary pharmaceutical stakeholders, adopting an integrated, evidence-based approach is essential to improve long-term outcomes, enhance patient quality of life, and optimize client satisfaction in this complex chronic disease.
Written by Marcos Rivas, PhD
Edited by Belén Colazo-Salbetti, PhD
References
Drechsler, Y., Dong, C., Clark, D. E., & Kaur, G. (2024). Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies. Veterinary medicine (Auckland, N.Z.), 15, 15–29. https://doi.org/10.2147/VMRR.S412570
Forster, S., Boegel, A., Despa, S., Trout, C., & King, S. (2025). Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary dermatology, 36(2), 165–176. https://doi.org/10.1111/vde.13319
To provide the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique identifiers on this site. Not consenting or withdrawing consent may negatively affect certain features and functions.
Functional
Siempre activo
Technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferencias
El almacenamiento o acceso técnico es necesario para la finalidad legítima de almacenar preferencias no solicitadas por el abonado o usuario.
Statistics
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos.Storage or technical access used exclusively for anonymous statistical purposes. Without a request, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Technical storage or access is necessary to create user profiles for sending advertising, or to track the user on a website or across several websites for similar marketing purposes.